Shahzad Raza on Muck Rack

Shahzad Raza

As seen in: Medium, Nature, MDPI, Dawn, Tribune (India), Daily Times, Times of Oman, HemOnc Today, ProPakistani, Dunya News and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shahzad

Contact Shahzad, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort

|
By Hossam Ali, Sandra Mazzoni, Utkarsh Goel, Jack Khouri, Faiz Anwer, Louis Williams, Christy Samaras, Beth Faiman, Kimberly Hamilton, Joslyn Rudoni, Mikhaila Rice, Jonathan Kissam, Cynthia Scott, Saveta Mathur, Alexandra Varney McDonald, Tara Roy, Julie Bevacqua, Marcelo C. Pasquini, Jason Valent, Shahzad Raza, Diana Basali, Willem Van Heeckeren
| Nature Verified
Patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment (RI) are considered a high-risk group frequently excluded from clinical trials. Patients with RI have a higher risk of disease progression or death compared to those without RI (relative risk (RR): 1.20 [1.003–1.431]) [1]. RI is a negative prognostic factor linked to early mortality, shorter overall survival (OS), and greater treatment-related toxicity.
Open in Who Shared Issue with article?

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

|
By Andrew J. Portuguese, James Davis, Shahzad Raza, Omar Castaneda Puglianini, Ciara L Freeman, Melissa Alsina, Corbin Wright, Brandon Blue, Rachid Baz, Kenneth H Shain, Utkarsh Goel, Jack Khouri, Faiz Anwer, Hossam Ali, Oren Pasvolsky, Mahmoud R. Gaballa, Damian Mikulski, Lindsay Fogel, Eli Zolotov, Aishwarya Sannareddy, Aimaz Afrough, Larry D. Jr, Kelley Julian, Danai Dima, Rahul Banerjee, Emily Liang, Raffaella Cassano, Megan Herr Verified, Hamza Hassan, Leyla O. Shune, Jeries Kort, Shonali Midha, Omar Nadeem, Surbhi Sidana, Yi Lin, Frederick Locke, Doris Hansen, Douglas Sborov, Noa Biran, Ariel Grajales-Cruz, Hector Garcia-Pleitez
| Nature Verified
Abstract Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies.
Open in Who Shared Issue with article?

VIDEO: Trial offers ‘a light’ for patients with extramedullary myeloma

|
By Shahzad Raza, Holly Vernyi
| HemOnc Today Verified
Ask a clinical question and tap into Healio AI's knowledge base. In this interview Shahzad Raza, MD, discusses a study on the treatment of patients with extramedullary myeloma, as presented at ASH 2025. “I found this to be a really exciting study. I don't think we can do this type of study in the future easily, because these are very complex and very challenging studies.
Open in Who Shared Issue with article?
See all 87 licensed articles (104 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified